Abstract: The present invention relates to a novel solid oral pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1H-purine-2,6-dione (Compound 1) as pharmaceutically active compound, a method for preparing the same and its use as a medicament. The novel solid oral pharmaceutical composition comprises Compound 1, a sugar alcohol and at least one further pharmaceutically acceptable excipient.

Abstract: The invention relates to solid pharmaceutical dosage forms comprising an extended release core comprising metformin hydrochloride and one or two immediate release coatings comprising linagliptin and/or empagliflozin.

Abstract: Formulations and intravitreal implants containing nintedanib can be used in methods for the treatment of back-of-the-eye diseases.

Abstract: In an embodiment, a fiduciary deposit business object may be used to manage data relating to cash flow instruments. The business object may be structured in an embodiment to include a plurality of tables, including transaction, collateral, activity, cash flow, and/or adjustment tables. In an embodiment, when a settlement activity is recorded in the business object, a financial calculation procedure may be initiated. The financial calculation procedure may use data stored in the tables in a financial calculation, such as a gain/loss calculation, based on the location of the data in a specific table, such as whether the data was recently added. After completing the financial calculation, data in the business object may be updated and/or a result may be sent to an accounting system. Additional data, such as data in the collateral and other tables, may also be sent to the accounting system depending on accounting reporting requirements.